Abstract
Intravenous thrombolysis reduces disability after acute ischaemic stroke, and efforts to identify new therapeutic agents that can improve outcomes while reducing the risk of haemorrhage are welcomed. Tenecteplase is a genetically modified tissue plasminogen activator that, compared with the standard-of-care alteplase, has higher fibrin specificity, a longer half-life, and reduced systemic coagulopathy. Thus, tenecteplase could potentially be associated with greater recanalisation and lower bleeding risk than alteplase.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
